MENU
+Compare
PBYI
Stock ticker: NASDAQ
AS OF
Dec 3 closing price
Price
$5.19
Change
+$0.32 (+6.57%)
Capitalization
261.53M

PBYI Puma Biotechnology Forecast, Technical & Fundamental Analysis

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients... Show more

Industry: #Biotechnology
PBYI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PBYI with price predictions
Nov 28, 2025

PBYI in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 07, 2025

PBYI broke above its upper Bollinger Band on November 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In of the 36 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PBYI moved out of overbought territory on November 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

PBYI moved below its 50-day moving average on November 19, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PBYI crossed bearishly below the 50-day moving average on November 21, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 26, 2025. You may want to consider a long position or call options on PBYI as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBYI just turned positive on November 28, 2025. Looking at past instances where PBYI's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.269) is normal, around the industry mean (27.312). P/E Ratio (7.014) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (1.226) is also within normal values, averaging (321.020).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBYI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
PBYI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PBYI is expected to report earnings to rise 30.71% to 27 cents per share on February 26

Puma Biotechnology PBYI Stock Earnings Reports
Q4'25
Est.
$0.27
Q3'25
Beat
by $0.05
Q2'25
Beat
by $0.06
Q4'24
Beat
by $0.32
Q3'24
Beat
by $0.13
The last earnings report on November 06 showed earnings per share of 20 cents, beating the estimate of 15 cents. With 453.21K shares outstanding, the current market capitalization sits at 261.53M.
A.I. Advisor
published General Information

General Information

operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10880 Wilshire Boulevard
Phone
+1 424 248-6500
Employees
185
Web
http://www.pumabiotechnology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CDNTF177.10N/A
N/A
Canadian Tire Corp. Ltd.
CODGF93.26N/A
N/A
Compagnie de Saint-Gobain
PRVCF0.02N/A
N/A
PreveCeutical Medical Inc.
RTOBF3.60N/A
N/A
Ratos AB
IRCDF1.37N/A
N/A
Intercede Group PLC

PBYI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with MTNB. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-1.71%
MTNB - PBYI
38%
Loosely correlated
+3.77%
DSGN - PBYI
33%
Loosely correlated
+0.11%
HRTX - PBYI
32%
Poorly correlated
+2.61%
NVAX - PBYI
31%
Poorly correlated
-1.49%
VRCA - PBYI
30%
Poorly correlated
-10.79%
More